Detalles de la búsqueda
1.
Regulatory and health technology assessment advice on postlicensing and postlaunch evidence generation is a foundation for lifecycle data collection for medicines.
Br J Clin Pharmacol
; 86(6): 1034-1051, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32162368
2.
Conditional Financing of Drugs in the Netherlands: Past, Present, and Future-Results From Stakeholder Interviews.
Value Health
; 22(4): 399-407, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30975390
3.
Social media as a tool for assessing patient perspectives on quality of life in metastatic melanoma: a feasibility study.
Health Qual Life Outcomes
; 16(1): 222, 2018 Nov 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-30497502
4.
What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews.
Value Health
; 20(7): 858-865, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28712614
5.
Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
Value Health
; 20(4): 520-532, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28407993
6.
Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making.
Value Health
; 20(8): 1003-1008, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28964430
7.
Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making.
Pharmacoepidemiol Drug Saf
; 26(9): 1033-1039, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28913966
8.
Public preferences for the allocation of societal resources over different healthcare purposes.
Soc Sci Med
; 341: 116536, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38176245
9.
Real world insights for psoriasis: the association of severity of skin lesions with work productivity, medical consumption costs and quality of life.
J Dermatolog Treat
; 35(1): 2332615, 2024 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38522860
10.
Cancer treatments touch a wide range of values that count for patients and other stakeholders: What are the implications for decision-making?
Cancer Med
; 12(5): 6105-6116, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36373590
11.
Are CAR-T therapies living up to their hype? A study using real-world data in two cohorts to determine how well they are actually working in practice compared with bone marrow transplants.
BMJ Evid Based Med
; 26(3): 98-102, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-31315904
12.
TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases.
Orphanet J Rare Dis
; 15(1): 127, 2020 05 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-32456653
13.
The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders.
PLoS One
; 14(11): e0225626, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31774854
14.
Use of medicine pricing and reimbursement policies for universal health coverage in Indonesia.
PLoS One
; 14(2): e0212328, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30779809
15.
Editorial: Novel methods and technologies for the evaluation of drug outcomes and policies.
Front Pharmacol
; 15: 1396034, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38698818
16.
Alignment of European Regulatory and Health Technology Assessments: A Review of Licensed Products for Alzheimer's Disease.
Front Med (Lausanne)
; 6: 73, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31134200
17.
Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology.
Eur J Cancer
; 114: 128-136, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31060925
18.
Use of Social Media in the Assessment of Relative Effectiveness: Explorative Review With Examples From Oncology.
JMIR Cancer
; 4(1): e11, 2018 Jun 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29884607
19.
Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies.
Pharmacoeconomics
; 36(3): 359-368, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29214389
20.
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer's Disease.
CNS Drugs
; 32(12): 1085-1090, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30467744